Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29184592 | 1.00 | HDAC6 (0.49) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL29184729 | 0.99 | HDAC6 (0.49) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL30807123 | 0.99 | HDAC6 (0.49) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL29184730 | 0.99 | HDAC6 (0.49) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL24754848 | 0.95 | HDAC1 (0.47) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL24754752 | 0.95 | HDAC1 (0.47) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL24754637 | 0.95 | HDAC6 (0.49) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL27431735 | 0.95 | HDAC6 (0.49) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL24754620 | 0.95 | HDAC6 (0.47) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL29184704 | 0.94 | HDAC1 (0.46) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633679-A1 | PEPTIDE DRUG CONJUGATES | Oncopeptides Innovation AB (SE) | 2025-10-22 | — | — | EP | claimed |
| US-20240316059-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES AB (SE) | 2024-09-26 | — | — | US | claimed |
| WO-2024126845-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES INNOVATION AB (SE) | 2024-06-20 | — | — | WO | claimed |
| WO-2024121379-A1 | NOVEL THERAPEUTIC COMBINATIONS | ONCOPEPTIDES INNOVATION AB (SE) | 2024-06-13 | — | — | WO | claimed |
| EP-4355370-A1 | PEPTIDE DRUG CONJUGATES | Oncopeptides Innovation AB (SE) | 2024-04-24 | — | — | EP | claimed |
| CN-117794580-A | Polypeptide coupling medicine | 肿瘤多肽有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2022263679-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES AB (SE) | 2022-12-22 | — | — | WO | claimed |
| EP-4633679-A1 | PEPTIDE DRUG CONJUGATES | Oncopeptides Innovation AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20240316059-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES AB (SE) | 2024-09-26 | — | — | US | disclosed |
| WO-2024126845-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES INNOVATION AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024121379-A1 | NOVEL THERAPEUTIC COMBINATIONS | ONCOPEPTIDES INNOVATION AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121379-A1 | NOVEL THERAPEUTIC COMBINATIONS | ONCOPEPTIDES INNOVATION AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| EP-4355370-A1 | PEPTIDE DRUG CONJUGATES | Oncopeptides Innovation AB (SE) | 2024-04-24 | — | — | EP | disclosed |
| CN-117794580-A | Polypeptide coupling medicine | 肿瘤多肽有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2022263679-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES AB (SE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263679-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES AB (SE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316059-A1 | PEPTIDE DRUG CONJUGATES | MCL1, DNPEP, VIP | HDAC6 627/4885HDAC1 2830/4885HDAC3 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.